📊 Note: Daily ratings and analytics are updated after market close and will be available by 7:00 PM IST.

Details

NameSymbolSector
AUROBINDO PHARMA LTD.AUROPHARMAPharmaceuticals
Open
1523
High
1550
Low
1515.5
Close
1546.7
Volume
1013775
Exchange
nse
Time
21-May-2026

Outlook

Score:

5.5

Rating:

FAIR

Candlestick Pattern

CandlepatternofAurobindoPharmais
Long Body
EstimatedStoplossofAurobindoPharmais
1515.5
AurobindoPharmahasa
Bullishℹ
pattern.
Formationof
Long Body
candlepatternindicatesAurobindoPharmahaschancesof
Continuationℹ
ofthecurrenttrend.

Trend

AurobindoPharmaisin
Uptrendℹ
.
PriceofAurobindoPharmais
Upℹ
by

10.33

%.
Target
Buy@

1266.1

Sell@

1550

Current@

1546.7

Volume

ThetradevolumesofAurobindoPharmahavebecome
Deficientℹ
ThoughthevolumetrendforAurobindoPharmaappears
Bullishℹ
theparticipantsseemtobe
Weak Buyersℹ
ThetradevolumeofAurobindoPharmais

Down

by

35.77

%

Valuation

ThecurrentmarketpriceofAurobindoPharmais
Undervaluedℹ

Financials

Balance
Withtotalliablitiesandshareholderequityworth49784crandtotalassetsworth49784cr,thebalancesheetofAurobindoPharmais:
Balancedℹ
.
Cashflow
AurobindoPharmahas
Maintainedℹ
cashflowbecausethereis

Surplus

of

₹ 2178cr

.Itis
Upℹ
by

316.5

%.
66.21% i.e. ₹ 3924cr earned in operatingℹ
31.63% i.e. ₹ 1875cr spent in investingℹ
2.01% i.e. ₹ 119cr earned in financingℹ
0.15% i.e. ₹ 9cr earned in otherℹ
AurobindoPharmahas
Poorℹ
cashflowbecausethereis

Shortage

of

₹ 1006cr

.Itis
Downℹ
by

539.3

%.
32.44% i.e. ₹ 2434cr earned in operatingℹ
56.71% i.e. ₹ 4255cr spent in investingℹ
10.66% i.e. ₹ 800cr earned in financingℹ
0.19% i.e. ₹ 14cr earned in otherℹ
Income
TheincomeofAurobindoPharmais

₹ 8406cr

and

Profit

is:

₹ 846cr

AurobindoPharmaProfitisupby:

2.92

%andIncomeisUpby:

5.43

%
TheincomeofAurobindoPharmais

₹ 7973cr

and

Profit

is:

₹ 822cr

AurobindoPharmaProfitisdownby:

12.09

%andIncomeisDownby:

6.38

%
TheincomeofAurobindoPharmais

₹ 8516cr

and

Profit

is:

₹ 935cr

AurobindoPharmaProfitisupby:

10.91

%andIncomeisUpby:

4.68

%
By using this site you agree to the use of cookies to deliver a better site experience.